Progerinin
Hutchinson-Gilford Progeria Syndrome
PRG Science & Technology Co., Ltd.Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hutchinson-Gilford Progeria Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PRAVASTATIN Boston Children's Hospital | Phase 2 | B |
Zoledronate Boston Children's Hospital | Phase 2 | B |
Lonafarnib PRG Science & Technology Co., Ltd. | Phase 2 | B |
Same molecule, other indications
Progerinin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →